Literature DB >> 23435834

Intraperitoneal hyperthermic chemotherapy: which drugs?

Jacopo Giuliani1.   

Abstract

Mesh：

Year:  2014        PMID： 23435834     DOI： 10.1007/s12029-013-9486-6

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  22 in total

1.  Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.

Authors:  F Raspagliesi; S Kusamura; J C Campos Torres; G A de Souza; A Ditto; F Zanaboni; R Younan; D Baratti; L Mariani; B Laterza; M Deraco
Journal:  Eur J Surg Oncol       Date:  2006-04-18       Impact factor: 4.424

2.  Intraperitoneal hyperthermic chemotherapy in ovarian cancer.

Authors:  J Gori; R Castaño; M Toziano; D Häbich; J Staringer; D G B De Quirós; N Felci
Journal:  Int J Gynecol Cancer       Date:  2005 Mar-Apr       Impact factor: 3.437

3.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

4.  Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

Authors:  Ki Sung Ryu; Jae Hoon Kim; Hyun Sun Ko; Jin Woo Kim; Woong Shick Ahn; Yong Gyu Park; Seung Jo Kim; Joon Mo Lee
Journal:  Gynecol Oncol       Date:  2004-08       Impact factor: 5.482

5.  Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.

Authors:  Tommaso Cioppa; Marco Vaira; Camilla Bing; Silvia D'Amico; Alessandro Bruscino; Michele De Simone
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

6.  Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators.

Authors:  C H Cho; P Wust; B Hildebrandt; R D Issels; J Sehouli; T Kerner; M Deja; V Budach; J Gellermann
Journal:  Int J Hyperthermia       Date:  2008-08       Impact factor: 3.914

7.  Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.

Authors:  O Glehen; V Schreiber; E Cotte; A C Sayag-Beaujard; D Osinsky; G Freyer; Y François; J Vignal; F N Gilly
Journal:  Arch Surg       Date:  2004-01

8.  Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.

Authors:  Dominique Elias; Diane Goéré; Daniela Di Pietrantonio; Valérie Boige; David Malka; Niaz Kohneh-Shahri; Clarisse Dromain; Michel Ducreux
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

9.  Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.

Authors:  Marcello Deraco; Paolo Casali; M G Inglese; Dario Baratti; Elisabetta Pennacchioli; Rossella Bertulli; Shigeki Kusamura
Journal:  J Surg Oncol       Date:  2003-07       Impact factor: 3.454

10.  Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.

Authors:  E Facchiano; S Scaringi; R Kianmanesh; J M Sabate; B Castel; Y Flamant; B Coffin; S Msika
Journal:  Eur J Surg Oncol       Date:  2007-07-20       Impact factor: 4.424
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.